RaQualia Pharma Inc.
4579.T · JPX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | ¥775,053 | ¥570,563 | ¥965,409 | ¥738,137 |
| % Growth | 35.8% | -40.9% | 30.8% | – |
| Cost of Goods Sold | ¥226,551 | ¥235,286 | ¥292,823 | ¥228,909 |
| Gross Profit | ¥548,502 | ¥335,277 | ¥672,586 | ¥509,228 |
| % Margin | 70.8% | 58.8% | 69.7% | 69% |
| R&D Expenses | ¥454,600 | ¥397,204 | ¥385,062 | ¥448,777 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥84,000 |
| SG&A Expenses | ¥248,453 | ¥221,375 | ¥194,416 | ¥246,612 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥703,053 | ¥618,579 | ¥579,478 | ¥695,389 |
| Operating Income | -¥154,551 | -¥283,302 | ¥93,108 | -¥186,161 |
| % Margin | -19.9% | -49.7% | 9.6% | -25.2% |
| Other Income/Exp. Net | ¥19,306 | -¥37,334 | -¥63,888 | ¥55,697 |
| Pre-Tax Income | -¥135,245 | -¥320,636 | ¥29,220 | -¥130,464 |
| Tax Expense | ¥78,992 | ¥28,895 | ¥34,435 | ¥24,673 |
| Net Income | -¥214,237 | -¥349,532 | -¥5,215 | -¥155,138 |
| % Margin | -27.6% | -61.3% | -0.5% | -21% |
| EPS | -8.76 | -15.25 | -0.24 | -7.16 |
| % Growth | 42.6% | -6,254.2% | 96.6% | – |
| EPS Diluted | -8.76 | -15.25 | -0.24 | -7.16 |
| Weighted Avg Shares Out | 24,457 | 22,923 | 21,838 | 21,667 |
| Weighted Avg Shares Out Dil | 24,457 | 22,923 | 21,838 | 21,667 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥5,645 | ¥4,788 | ¥4,162 | ¥2,861 |
| Interest Expense | ¥15,247 | ¥16,208 | ¥14,973 | ¥14,003 |
| Depreciation & Amortization | ¥120,855 | ¥119,393 | ¥117,852 | ¥121,359 |
| EBITDA | ¥856 | -¥185,035 | ¥162,046 | ¥4,896 |
| % Margin | 0.1% | -32.4% | 16.8% | 0.7% |